Business
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a
About this update from Alpha Cognition Inc.
[{"type":"text","content":" VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--\nAlpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists (AAGP), taking place April 16-20, 2026 and the Neuroscience Education Institute (NEI) Spring Congress, taking place May 1-3, 2026.\n\n\nThe Company will share the following poster presentations:\n\n\nBeyond Cholinesterase Inhibition: The Clinical Benefits of Galantamine- and Benzgalantamine-Mediated Nicotinic Receptor Modulation in Alzheimer’s Disease\nPresenter: Kurt Grady, PharmD (Poster S49)\nPresentation: April 18, 5:30pm EST\n\n\nLiterature Review: Acetylcholinesterase Inhibitors and Delayed Nursing Home Placement in Alzheimer’s Disease\nPresenter: Pavel Svintozelskiy, PharmD (Poster S45)\nPresentation: April 18, 5:30pm EST\n\n\nAcetylcholinesterase Inhibitors and Psychotropic Medication Use in Alzheimer’s Disease and Related Dementias (ADRD)\nPresenter: Pavel Svintozelskiy, PharmD\nPresentation: May 2, 9:45am EST\n\n\nAcetylcholinesterase Inhibitor Persistence: The Value of Sustained Therapy in Alzheimer’s Disease and Related Dementias\nPresenter: Kurt Grady, PharmD\nPresentation: May 2, 9:45am EST\n\n\n“We’re excited to present new data on ZUNVEYL at these upcoming conferences, further characterizing its clinical profile in patients with Alzheimer’s disease,” said Dennis Kay, PhD, Chief Scientific Officer of Alpha Cognition. “These findings build on our understanding of ZUNVEYL’s potential and reinforce our commitment to improving outcomes for patients and caregivers through innovative approaches. We look forward to engaging with the scientific and medical community as we continue to support its integration into real-world treatment settings.”\n\n\nAbout Alpha Cognition Inc.\n\n\nAlpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.\n\n\nALPHA-1062 formulated as a delayed release oral tablet (ZUNVEYL), ...